Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 35108059

Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
J Clin Oncol
Publication date
2022 Apr 20
First author
Spigel DR

This record carries publication-notice metadata. Review the notices below before relying on it.

Publication notices

absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    J Clin Oncol. 2022 Apr 20;40(12):1271-1274. doi: 10.1200/JCO.22.00204.
    note
    Source null
    related pmid
    35239424
    relationship
    Comment in
  2. citation
    J Clin Oncol. 2022 Jun 10;40(17):1965. doi: 10.1200/JCO.22.01023.
    note
    Source null
    related pmid
    35671538
    relationship
    Erratum in

Authors and identifiers

  1. name
    Spigel DR
    type
    Author
  2. name
    Faivre-Finn C
    type
    Author
  3. name
    Gray JE
    type
    Author
  4. name
    Vicente D
    type
    Author
  5. name
    Planchard D
    type
    Author
  6. name
    Paz-Ares L
    type
    Author
  7. name
    Vansteenkiste JF
    type
    Author
  8. name
    Garassino MC
    type
    Author
  9. name
    Hui R
    type
    Author
  10. name
    Quantin X
    type
    Author
  11. name
    Rimner A
    type
    Author
  12. name
    Wu YL
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Spigel DR
    type
    Author
  2. name
    Faivre-Finn C
    type
    Author
  3. name
    Gray JE
    type
    Author
  4. name
    Vicente D
    type
    Author
  5. name
    Planchard D
    type
    Author
  6. name
    Paz-Ares L
    type
    Author
  7. name
    Vansteenkiste JF
    type
    Author
  8. name
    Garassino MC
    type
    Author
  9. name
    Hui R
    type
    Author
  10. name
    Quantin X
    type
    Author
  11. name
    Rimner A
    type
    Author
  12. name
    Wu YL
    type
    Author
bibliography ids
  1. nci-bib-555b328f1c4abc1a6d8b61d0
book metadata
content sha256
4aa1fcefcbfae1fe1c2fa673ed18299303a4a5363d93f990fd6b76b05e0c7156
document type
citation
dois
  1. 10.1200/JCO.21.01308
electronic publication date
display
2022 Feb 2
precision
day
year
2022
evidence scope
bibliographic_metadata_only
id
pubmed:35108059
immutable id
pubmed:35108059@4aa1fcefcbfae1fe1c2fa673ed18299303a4a5363d93f990fd6b76b05e0c7156
journal
abbreviation
J Clin Oncol
issn electronic
1527-7755
issn print
0732-183X
issue
12
name
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
nlm unique id
8309333
pages
1301-1311
volume
40
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    J Clin Oncol. 2022 Apr 20;40(12):1271-1274. doi: 10.1200/JCO.22.00204.
    note
    Source null
    related pmid
    35239424
    relationship
    Comment in
  2. citation
    J Clin Oncol. 2022 Jun 10;40(17):1965. doi: 10.1200/JCO.22.01023.
    note
    Source null
    related pmid
    35671538
    relationship
    Erratum in
outcomes validated
false
pmid
35108059
provenance
batch id
3f4d1914d2afe41e9e70
provider
NCBI PubMed ESummary
record sha256
9306b5eb7c7db7bb7fa8e5c3d237d0700856754ab5956ac0303f8a84e7c98ca3
response sha256
0ceeb248a527e54c6f72dd28d20f7abec08a973fe2e10de00bede4895add09e7
retrieved at
2026-09-09T23:48:06.522634+00:00
publication date
display
2022 Apr 20
precision
day
year
2022
publication types
  1. Journal Article
  2. Randomized Controlled Trial
  3. Research Support, N.I.H., Extramural
  4. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/35108059/
title
Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.

Preserved source evidence · Not medical advice